Q4 EPS Estimate for United Therapeutics Lowered by Analyst

United Therapeutics Co. (NASDAQ:UTHR) – Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for United Therapeutics in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings of $6.90 per share for the quarter, down from their prior forecast of $7.77. The consensus estimate for United Therapeutics’ current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q4 2025 earnings at $7.85 EPS.

UTHR has been the topic of a number of other reports. HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Argus upped their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. The Goldman Sachs Group upped their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Finally, Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $382.08.

United Therapeutics Price Performance

United Therapeutics stock opened at $370.44 on Thursday. The stock’s 50 day moving average is $361.91 and its 200 day moving average is $358.41. The firm has a market cap of $16.54 billion, a P/E ratio of 16.27, a P/E/G ratio of 0.92 and a beta of 0.57. United Therapeutics has a one year low of $211.61 and a one year high of $417.82.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Milestone Asset Management LLC lifted its position in shares of United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 1,037 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in shares of United Therapeutics by 9.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock valued at $3,326,000 after buying an additional 789 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after buying an additional 50,291 shares during the last quarter. Franklin Resources Inc. lifted its holdings in United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Finally, Burney Co. lifted its holdings in United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after purchasing an additional 12,705 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares in the company, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,485,785.60. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 121,864 shares of company stock worth $44,516,965. 11.90% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.